Logos Global Management LP Bicycle Therapeutics PLC Transaction History

Logos Global Management LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$18.95 - $28.67 $4.36 Million - $6.59 Million	-230,000 Reduced 30.67%	520,000 $13.3 Million
Q1 2023 May 15, 2023	SELL	$20.02 - $31.37 $13.7 Million - $21.5 Million	-685,000 Reduced 47.74%	750,000 $16 Million
Q4 2022 Feb 14, 2023	SELL	$20.37 - $32.9 $11.5 Million - $18.6 Million	-565,000 Reduced 28.25%	1,435,000 $42.5 Million
Q3 2022 Nov 14, 2022	BUY	$17.49 - $28.44 $5.25 Million - $8.53 Million	300,000 Added 17.65%	2,000,000 $46.5 Million
Q2 2022 Aug 15, 2022	BUY	$12.95 - $46.99 $9.71 Million - $35.2 Million	750,000 Added 78.95%	1,700,000 $28.5 Million
Q1 2022 May 16, 2022	BUY	$40.12 - $59.5 $3.21 Million - $4.76 Million	80,000 Added 9.2%	950,000 $41.7 Million
Q4 2021 Feb 14, 2022	SELL	$41.7 - $61.14 $25.2 Million - $37 Million	-605,000 Reduced 41.02%	870,000 $53 Million
Q3 2021 Nov 15, 2021	BUY	$27.95 - $44.24 $21.2 Million - $33.6 Million	760,000 Added 106.29%	1,475,000 $61.3 Million
Q2 2021 Aug 16, 2021	SELL	$27.0 - $32.28 $2.3 Million - $2.74 Million	-85,000 Reduced 10.63%	715,000 $21.7 Million
Q1 2021 May 17, 2021	BUY	$19.12 - $30.25 $15.3 Million - $24.2 Million	800,000 New	800,000 $23.9 Million

111

40.7M

3.4K

12.4K

Ticker BCYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,676,100
Market Cap $674M
Description
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The co...

Get notified when there are updates to the investment portfolio of Logos Global Management LP, based on Form 13F filings with the SEC.

Stay updated on Logos Global Management LP with notifications on news.